Dutch-based Corporis Medical raises €4M to develop and commercialise medical devices for minimally invasive surgery

Maastricht-based Corporis Medical, a startup that focuses on developing and commercialising medical devices for minimally invasive surgery, announced that it has closed €4M in a Series B round of funding.

The Dutch medtech startup completes the all-equity financing round, including the conversion of existing convertible loans.

Texas-based VC firm Unorthodox Ventures led the round and was joined by existing investors Brightlands Venture Partners and LIOF.

“Minimise post-operative complications with smarter surgical tools”

Founded in 2015 by John Marugg and Alexander Veenhof, Corporis Medical is a medtech company based at the Brightlands Maastricht Health Campus. It specialises in developing and commercialising medical devices to enhance surgical outcomes.

Focused on improving safety, efficacy, and ease for surgeons, the startup’s solutions aim to save lives and reduce healthcare costs associated with surgery. It focuses on innovative surgical tools for enhanced wound healing in laparoscopic surgery.

Their product lineup includes the Mediclose System for automatic trocar closure and the Laprixa System, the world’s smallest tissue blood pressure measuring system. 

The Laprixa System offers surgeons a quantitative and patient-specific prediction of intraoperative wound healing capacity.

“Surgical wounds heal better and faster when there is sufficient blood flow, therefore we developed Laprixa, which can provide a quick and easy way to determine if good wound healing is possible. As such, Laprixa will become a game-changer in surgical wound healing,” says the startup.

Currently, Corporis Medical is undergoing regulatory and clinical validation processes in preparation for market launch.

Capital utilisation

Corporis Medical secures funding to advance clinical trials for a Randomised Controlled Trial for Mediclose and clinical validation of the fully integrated Laprixa System. The funds will also help the startup in speeding up regulatory filings.

John Marugg, CEO of Corporis Medical says, “We are pleased that Unorthodox Ventures and our current stakeholders have shown unwavering confidence in our products that improve outcomes of surgical interventions.”

“This round of funding will allow us to take important steps necessary to enable a market launch.”